Home › Funds › Logos Global Management LP › ELVN

Logos Global Management LP position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Logos Global Management LP reported holding 465,000 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$23.6M, representing 1.02% of its reported portfolio and ranking #32 among its reported holdings. Logos Global Management LP has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)465.00K sh
Reported value held$23.60M
Portfolio Weight1.02%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Logos Global Management LP's ELVN position evolved

Logos Global Management LP first disclosed a stake in ELVN in Q3 2023 at 307,076 shares (US$4.2M). The position peaked in Q1 2024 at 1,574,220 shares, worth US$26.4M. Across 12 filings, Logos Global Management LP increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 465,000 shares valued at US$23.6M — a reduction of -35,000 shares quarter over quarter.. Notable position changes include a 413% increase in Q1 2024 (shares rose 33% over the following quarter), a 72% trim in Q4 2024 (shares fell 13% over the following quarter), a 71% increase in Q1 2025 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 307.08K $4.19M New
Q4 2023 307.08K $4.25M Hold
Q1 2024 1.57M $26.41M Add
Q2 2024 595.00K $13.91M Reduce
Q3 2024 495.00K $12.64M Reduce
Q4 2024 140.00K $3.15M Reduce
Q1 2025 240.00K $4.72M Add
Q2 2025 350.00K $7.02M Add
Q3 2025 340.00K $6.96M Reduce
Q4 2025 340.00K $5.24M Hold
Q1 2026 500.00K $19.60M Add
Q2 2026 465.00K $23.60M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Logos Global Management LP held ELVN?

Logos Global Management LP has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Logos Global Management LP's current position in ELVN?

As of Q2 2026, Logos Global Management LP holds 465.00K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $23.60M, representing 1.02% of its reported portfolio and ranking #32.

Has Logos Global Management LP been buying or selling ELVN?

In the latest 13F filing (Q2 2026), Logos Global Management LP reduced its position in ELVN. The position peaked in Q1 2024 at 1.57M shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.